Compare Aurobindo Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs UNICHEM LAB - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA UNICHEM LAB AUROBINDO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 18.7 -40.8 - View Chart
P/BV x 4.0 1.0 403.9% View Chart
Dividend Yield % 0.3 1.4 18.8%  

Financials

 AUROBINDO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
UNICHEM LAB
Mar-19
AUROBINDO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs830292 284.2%   
Low Rs527182 289.6%   
Sales per share (Unadj.) Rs333.9167.7 199.1%  
Earnings per share (Unadj.) Rs40.4-3.6 -1,111.5%  
Cash flow per share (Unadj.) Rs51.85.9 871.1%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Dividend yield (eoy) %0.41.7 21.8%  
Book value per share (Unadj.) Rs237.1372.3 63.7%  
Shares outstanding (eoy) m585.9170.38 832.5%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.01.4 143.8%   
Avg P/E ratio x16.8-65.3 -25.8%  
P/CF ratio (eoy) x13.139.9 32.9%  
Price / Book Value ratio x2.90.6 449.5%  
Dividend payout %6.2-110.2 -5.6%   
Avg Mkt Cap Rs m397,56916,680 2,383.5%   
No. of employees `00017.92.6 686.2%   
Total wages/salary Rs m25,8492,393 1,080.1%   
Avg. sales/employee Rs Th10,956.94,535.2 241.6%   
Avg. wages/employee Rs Th1,447.7919.8 157.4%   
Avg. net profit/employee Rs Th1,324.3-98.2 -1,348.5%   
INCOME DATA
Net Sales Rs m195,63611,801 1,657.9%  
Other income Rs m1,553984 157.8%   
Total revenues Rs m197,18912,785 1,542.4%   
Gross profit Rs m39,519-835 -4,733.4%  
Depreciation Rs m6,680674 991.5%   
Interest Rs m2,62675 3,492.0%   
Profit before tax Rs m31,767-600 -5,297.2%   
Minority Interest Rs m270-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,269-343 -2,116.2%   
Profit after tax Rs m23,645-256 -9,253.3%  
Gross profit margin %20.2-7.1 -285.5%  
Effective tax rate %22.957.3 39.9%   
Net profit margin %12.1-2.2 -558.1%  
BALANCE SHEET DATA
Current assets Rs m153,64520,384 753.7%   
Current liabilities Rs m120,4295,029 2,394.6%   
Net working cap to sales %17.0130.1 13.0%  
Current ratio x1.34.1 31.5%  
Inventory Days Days135105 129.1%  
Debtors Days Days64135 47.2%  
Net fixed assets Rs m103,9099,023 1,151.6%   
Share capital Rs m586141 416.1%   
"Free" reserves Rs m138,32226,058 530.8%   
Net worth Rs m138,90826,199 530.2%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54431,496 839.9%  
Interest coverage x13.1-7.0 -187.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.4 197.4%   
Return on assets %9.9-0.6 -1,734.5%  
Return on equity %17.0-1.0 -1,745.2%  
Return on capital %23.8-2.0 -1,192.2%  
Exports to sales %49.669.4 71.5%   
Imports to sales %18.80-   
Exports (fob) Rs m97,0918,188 1,185.8%   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3168,188 1,188.5%   
Fx outflow Rs m40,589596 6,810.3%   
Net fx Rs m56,7277,592 747.2%   
CASH FLOW
From Operations Rs m16,220-3,278 -494.9%  
From Investments Rs m-28,768-2,860 1,005.8%  
From Financial Activity Rs m19,191-24 -79,300.0%  
Net Cashflow Rs m6,656-4,690 -141.9%  

Share Holding

Indian Promoters % 54.1 50.1 108.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 15.1 52.6%  
FIIs % 27.7 3.0 923.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 31.7 32.2%  
Shareholders   69,601 20,176 345.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  SUN PHARMA  IPCA LABS  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 27, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS